Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy January 12, 2026 8:00 AM EST
Company Participants
Louis Tamayo – CFO & Principal Accounting Officer
R. Townsend – CEO & Director
Eric Adler – Chief Medical Officer & Head of Research
Conference Call Participants
Matthew Ryan Tan – Stifel, Nicolaus & Company, Incorporated, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Christopher Raymond – Raymond James & Associates, Inc., Research Division
Moritz Reiterer – Guggenheim Securities, LLC, Research Division
Geulah Livshits – Chardan Capital Markets, LLC, Research Division
Michael Obodai
Rohan Mathur – Oppenheimer & Co. Inc., Research Division
Presentation
Operator
Good morning, and welcome to Lexeo Therapeutics webcast presentation on LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. As a reminder, this call is being recorded today, January 12.
I would now like to turn the conference call over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead.
Louis Tamayo
CFO & Principal Accounting Officer
Earlier today, we released interim data from the Lexeo HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy or ACM. The press release outlining the interim data update is available on our website at lexeotx.com as well as the slides related to today’s call. Joining us on today’s call will be Nolan Townsend, Chief Executive Officer; and Dr. Eric Adler, Head of Research.
Before we begin, I would like to remind you that this call will contain forward-looking statements regarding Lexeo’s future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various
Read the full article here
